BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 30952205)

  • 1. Identification of Hürthle cell cancers: solving a clinical challenge with genomic sequencing and a trio of machine learning algorithms.
    Hao Y; Duh QY; Kloos RT; Babiarz J; Harrell RM; Traweek ST; Kim SY; Fedorowicz G; Walsh PS; Sadow PM; Huang J; Kennedy GC
    BMC Syst Biol; 2019 Apr; 13(Suppl 2):27. PubMed ID: 30952205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of the Afirma genomic sequencing classifier versus gene expression classifier: An institutional experience.
    Wei S; Veloski C; Sharda P; Ehya H
    Cancer Cytopathol; 2019 Nov; 127(11):720-724. PubMed ID: 31536167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of the Afirma Gene Expression Classifier in Hürthle Cell Thyroid Nodules Differs from Other Indeterminate Thyroid Nodules.
    Brauner E; Holmes BJ; Krane JF; Nishino M; Zurakowski D; Hennessey JV; Faquin WC; Parangi S
    Thyroid; 2015 Jul; 25(7):789-96. PubMed ID: 25962906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hurthle cell predominance impacts results of Afirma gene expression classifier and ThyroSeq molecular panel performance in indeterminate thyroid nodules.
    Parajuli S; Jug R; Ahmadi S; Jiang XS
    Diagn Cytopathol; 2019 Nov; 47(11):1177-1183. PubMed ID: 31348619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fine-needle aspiration biopsy of Hurthle cell lesions of the thyroid gland: A cytomorphologic study of 139 cases with statistical analysis.
    Elliott DD; Pitman MB; Bloom L; Faquin WC
    Cancer; 2006 Apr; 108(2):102-9. PubMed ID: 16453320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fine-needle aspiration biopsy specimen with a predominance of Hürthle cells: a dilemma in the management of nodular thyroid disease.
    Alaedeen DI; Khiyami A; McHenry CR
    Surgery; 2005 Oct; 138(4):650-6; discussion 656-7. PubMed ID: 16269293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Independent Comparison of the Afirma Genomic Sequencing Classifier and Gene Expression Classifier for Cytologically Indeterminate Thyroid Nodules.
    Angell TE; Heller HT; Cibas ES; Barletta JA; Kim MI; Krane JF; Marqusee E
    Thyroid; 2019 May; 29(5):650-656. PubMed ID: 30803388
    [No Abstract]   [Full Text] [Related]  

  • 8. Performance of Afirma genomic sequencing classifier vs gene expression classifier in Bethesda category III thyroid nodules: An institutional experience.
    Zhang L; Smola B; Lew M; Pang J; Cantley R; Pantanowitz L; Heider A; Jing X
    Diagn Cytopathol; 2021 Aug; 49(8):921-927. PubMed ID: 34021740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Afirma Gene Sequencing Classifier Compared with Gene Expression Classifier in Indeterminate Thyroid Nodules.
    Endo M; Nabhan F; Porter K; Roll K; Shirley LA; Azaryan I; Tonkovich D; Perlick J; Ryan LE; Khawaja R; Meng S; Phay JE; Ringel MD; Sipos JA
    Thyroid; 2019 Aug; 29(8):1115-1124. PubMed ID: 31154940
    [No Abstract]   [Full Text] [Related]  

  • 10. The Presence of Hürthle Cells Does Not Increase the Risk of Malignancy in Most Bethesda Categories in Thyroid Fine-Needle Aspirates.
    Ren Y; Kyriazidis N; Faquin WC; Soylu S; Kamani D; Saade R; Torchia N; Lubitz C; Davies L; Stathatos N; Stephen AE; Randolph GW
    Thyroid; 2020 Mar; 30(3):425-431. PubMed ID: 32013786
    [No Abstract]   [Full Text] [Related]  

  • 11. Analytical Performance of a Gene Expression Classifier for Medullary Thyroid Carcinoma.
    Pankratz DG; Hu Z; Kim SY; Monroe RJ; Wong MG; Traweek ST; Kloos RT; Walsh PS; Kennedy GC
    Thyroid; 2016 Nov; 26(11):1573-1580. PubMed ID: 27605259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malignancy risk for solitary and multiple nodules in Hürthle cell-predominant thyroid fine-needle aspirations: A multi-institutional study.
    Wong KS; Jo VY; Lowe AC; Faquin WC; Renshaw AA; Shah AA; Roh MH; Stelow EB; Krane JF
    Cancer Cytopathol; 2020 Jan; 128(1):68-75. PubMed ID: 31751003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prevalence and surgical outcomes of Hürthle cell lesions in FNAs of the thyroid: A multi-institutional study in 6 Asian countries.
    Agarwal S; Bychkov A; Jung CK; Hirokawa M; Lai CR; Hong S; Kwon HJ; Rangdaeng S; Liu Z; Su P; Kakudo K; Jain D
    Cancer Cytopathol; 2019 Mar; 127(3):181-191. PubMed ID: 30668897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hürthle cell lesions on thyroid fine needle aspiration cytology: Molecular and histologic correlation.
    Schatz-Siemers N; Brandler TC; Oweity T; Sun W; Hernandez A; Levine P
    Diagn Cytopathol; 2019 Oct; 47(10):977-985. PubMed ID: 31293091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analytical validation of the Percepta genomic sequencing classifier; an RNA next generation sequencing assay for the assessment of Lung Cancer risk of suspicious pulmonary nodules.
    Johnson MK; Wu S; Pankratz DG; Fedorowicz G; Anderson J; Ding J; Wong M; Cao M; Babiarz J; Lofaro L; Walsh PS; Kennedy GC; Huang J
    BMC Cancer; 2021 Apr; 21(1):400. PubMed ID: 33849470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic performances of the Afirma Gene Sequencing Classifier in comparison with the Gene Expression Classifier: A meta-analysis.
    Vuong HG; Nguyen TPX; Hassell LA; Jung CK
    Cancer Cytopathol; 2021 Mar; 129(3):182-189. PubMed ID: 32726885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration?
    Pu RT; Yang J; Wasserman PG; Bhuiya T; Griffith KA; Michael CW
    Diagn Cytopathol; 2006 May; 34(5):330-4. PubMed ID: 16604553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of Hürthle cells in fine needle aspiration biopsy for multinodular goitre.
    Keskek M; Ocak S; Ozalp N; Koc M; Tez M
    Endocr Regul; 2010 Apr; 44(2):65-8. PubMed ID: 20429635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. STATISTICAL COMPARISON OF AFIRMA GSC AND AFIRMA GEC OUTCOMES IN A COMMUNITY ENDOCRINE SURGICAL PRACTICE: EARLY FINDINGS.
    Harrell RM; Eyerly-Webb SA; Golding AC; Edwards CM; Bimston DN
    Endocr Pract; 2019 Feb; 25(2):161-164. PubMed ID: 30383497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "Copy number alteration" as the sole molecular finding of a Thyroseq test is more commonly seen in Hurthle cell neoplasms.
    Kim TH; Rodriguez EF; Lim D; Moatamed NA
    Diagn Cytopathol; 2023 Nov; 51(11):705-711. PubMed ID: 37533334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.